Skip to main content

Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.

Publication ,  Journal Article
Mor, A; Bingham, CO; Barisoni, L; Lydon, E; Belmont, HM
Published in: J Rheumatol
April 2005

Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.

Duke Scholars

Published In

J Rheumatol

ISSN

0315-162X

Publication Date

April 2005

Volume

32

Issue

4

Start / End Page

740 / 743

Location

Canada

Related Subject Headings

  • Withholding Treatment
  • Vasculitis, Leukocytoclastic, Cutaneous
  • Recombinant Fusion Proteins
  • Receptors, Tumor Necrosis Factor
  • Lupus Nephritis
  • Immunoglobulin G
  • Immunocompromised Host
  • Humans
  • Female
  • Etanercept
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mor, A., Bingham, C. O., Barisoni, L., Lydon, E., & Belmont, H. M. (2005). Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol, 32(4), 740–743.

Published In

J Rheumatol

ISSN

0315-162X

Publication Date

April 2005

Volume

32

Issue

4

Start / End Page

740 / 743

Location

Canada

Related Subject Headings

  • Withholding Treatment
  • Vasculitis, Leukocytoclastic, Cutaneous
  • Recombinant Fusion Proteins
  • Receptors, Tumor Necrosis Factor
  • Lupus Nephritis
  • Immunoglobulin G
  • Immunocompromised Host
  • Humans
  • Female
  • Etanercept